Allyl methacrylate (AMA) is a colorless liquid monomer with a pungent odor. It is synthesized through the esterification of methacrylic acid with allyl alcohol. AMA is a versatile monomer used in various applications, including the production of polymers, resins, and coatings. Its ability to undergo both free-radical and cationic polymerization makes it suitable for a wide range of applications. AMA is used in the production of dental materials, adhesives, sealants, and UV-curable coatings. Its unique properties, such as high reactivity and excellent adhesion, make it a valuable material for these applications. The polymerization of AMA can be initiated by both chemical and photochemical methods. The resulting polymers exhibit excellent mechanical strength, good chemical resistance, and optical transparency. The study of AMA is important due to its wide range of applications and the potential for developing new and improved materials with unique properties. AMA is also being investigated for its use in various biomedical applications, including drug delivery and tissue engineering. Due to its biocompatibility and ease of modification, AMA is considered a promising material for these applications.'
| ID Source | ID |
|---|---|
| PubMed CID | 7274 |
| CHEMBL ID | 1889548 |
| SCHEMBL ID | 22017 |
| MeSH ID | M0108492 |
| Synonym |
|---|
| 2-propenoic acid, 2-methyl-, 2-propenyl ester |
| prop-2-en-1-yl 2-methylprop-2-enoate |
| brn 1747406 |
| hsdb 5297 |
| nsc 18597 |
| einecs 202-473-0 |
| allylester kyseliny methakrylove [czech] |
| ageflex ama |
| allyl 2-methylacrylate |
| ai3-37827 |
| methacrylic acid, allyl ester |
| allyl methacrylate |
| nsc-18597 |
| wln: 1uy1&vo2u1 |
| nsc18597 |
| 96-05-9 |
| NCGC00166051-01 |
| allyl methacrylate, contains 50-185 ppm mehq as inhibitor, 98% |
| prop-2-enyl 2-methylprop-2-enoate |
| M0075 |
| methacrylic acid allyl ester |
| NCGC00166051-02 |
| NCGC00256503-01 |
| dtxcid401816 |
| dtxsid2021816 , |
| tox21_302944 |
| cas-96-05-9 |
| tox21_201759 |
| NCGC00259308-01 |
| AKOS005207053 |
| ec 202-473-0 |
| 2-propenoic acid, 2-methyl-, 2-propen-1-yl ester |
| g2ig50653z , |
| allylester kyseliny methakrylove |
| unii-g2ig50653z |
| 3-methacryloyloxypropylene |
| 2-methyl-2-propenoic acid 2-propenyl ester |
| allyl methacrylate [inci] |
| allyl alcohol, methacrylate |
| SCHEMBL22017 |
| allyl ester of methacrylic acid |
| 2-methyl-2-propenyl 2-propenoate |
| allyl-methacrylate |
| allylmethacrylate |
| CHEMBL1889548 |
| Q2718014 |
| mfcd00008592 |
| allyl methacrylate (stabilized with mehq) |
| allyl methacrylate, (stabilized with mehq) |
| 2-propenyl 2-methylpropenoate |
| AMY4149 |
| methacrylic acid allyl ester (stabilized with mehq) |
| Excerpt | Reference | Relevance |
|---|---|---|
| " No mortalities and no significant adverse effects were observed in the low dose and control rabbits." | ( Subchronic dermal toxicity study of allyl methacrylate in rabbits. Hobbs, EJ; Siddiqui, WH, 1982) | 0.54 |
| " In the present study, GSH depletion in primary rat hepatocytes was used as an in vitro effect-equivalent to measure the toxic potency of alpha,beta-unsaturated esters (acrylates and methacrylates)." | ( Glutathione depletion in rat hepatocytes: a mixture toxicity study with alpha, beta-unsaturated esters. Freidig, A; Hermens, J; Hofhuis, M; Van Holstijn, I, 2001) | 0.31 |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| GLI family zinc finger 3 | Homo sapiens (human) | Potency | 27.3060 | 0.0007 | 14.5928 | 83.7951 | AID1259369 |
| retinoid X nuclear receptor alpha | Homo sapiens (human) | Potency | 44.9024 | 0.0008 | 17.5051 | 59.3239 | AID1159527; AID1159531 |
| estrogen-related nuclear receptor alpha | Homo sapiens (human) | Potency | 1.1326 | 0.0015 | 30.6073 | 15,848.9004 | AID1224841 |
| estrogen nuclear receptor alpha | Homo sapiens (human) | Potency | 23.4660 | 0.0002 | 29.3054 | 16,493.5996 | AID743069; AID743078 |
| activating transcription factor 6 | Homo sapiens (human) | Potency | 0.1142 | 0.1434 | 27.6121 | 59.8106 | AID1159516 |
| thyroid hormone receptor beta isoform 2 | Rattus norvegicus (Norway rat) | Potency | 22.5974 | 0.0003 | 23.4451 | 159.6830 | AID743066 |
| DNA polymerase kappa isoform 1 | Homo sapiens (human) | Potency | 16.8336 | 0.0316 | 22.3146 | 100.0000 | AID588579 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 1 (20.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (40.00) | 29.6817 |
| 2010's | 1 (20.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.
| This Compound (41.77) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||